Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer

Abstract

Among patients with heavily pretreated TNBC, Cy prior to pembrolizumab did not significantly deplete T_regs, and in those with decreased numbers there was rapid recovery following therapy. Increased B cell gene expression in baseline samples was associated with clinical response and IRT.